Exhibit 99.3

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

AS OF MARCH 31, 2026

TABLE OF CONTENTS

	Page

Condensed Consolidated interim Statements of Financial Position	F-2

Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income	F-3

Condensed Consolidated interim Statements of Changes in Equity	F-4 - F-5

Condensed Consolidated interim Statements of Cash Flows	F-6 - F-7

Notes to the Interim Consolidated Financial Statements	F-8 - F-13

- - - - - - - - - - -

F-1

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

	As of						As of
	March 31,						December 31,
	2026			2025			2025
	Unaudited
	U.S. Dollars in Thousands
Assets
Current Assets
Cash and cash equivalents	$	32,922		$	76,250		$	75,469
Short-term investments		40,225			-			-
Trade receivables, net		36,515			27,876			27,007
Other accounts receivables		4,136			6,016			5,656
Inventories		85,437			78,358			84,943
Total Current Assets		199,235			188,500			193,075

Non-Current Assets
Property, plant and equipment, net		41,463			37,406			41,367
Right-of-use assets		8,908			9,539			8,900
Intangible assets and other long-term assets		95,676			101,422			97,511
Goodwill		30,313			30,313			30,313
Contract assets		7,426			7,925			7,544
Total Non-Current Assets		183,786			186,605			185,635
Total Assets	$	383,021		$	375,105		$	378,710
Liabilities
Current Liabilities
Current maturities of lease liabilities	$	2,198		$	1,780		$	2,121
Current maturities of other long term liabilities		10,643			10,889			9,923
Trade payables		21,938			24,854			23,242
Other accounts payables		24,930			19,319			12,108
Deferred revenues		67			205			-
Total Current Liabilities		59,776			57,047			47,394

Non-Current Liabilities
Lease liabilities		9,443			9,318			9,440
Contingent consideration		20,910			21,216			20,372
Other long-term liabilities		29,925			32,990			30,113
Deferred taxes		2,866			2,061			1,651
Employee benefit liabilities, net		714			516			670
Total Non-Current Liabilities		63,858			66,101			62,246

Shareholder’s Equity
Ordinary shares		15,078			15,074			15,078
Additional paid in capital net		268,360			268,160			268,283
Capital reserve due to translation to presentation currency		(3,490	)		(3,490	)		(3,490	)
Capital reserve from hedges		(6	)		(117	)		177
Capital reserve from share-based payments		6,434			5,266			5,711
Capital reserve from employee benefits		374			372			385
Accumulated deficit		(27,363	)		(33,308	)		(17,074	)
Total Shareholder’s Equity		259,387			251,957			269,070
Total Liabilities and Shareholder’s Equity	$	383,021		$	375,105		$	378,710

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-2

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Three months period ended						Year ended
	March 31,						December 31,
	2026			2025			2025
	Unaudited
	U.S. Dollars in Thousands
Revenues from proprietary products	$	36,227		$	40,017		$	156,206
Revenues from distribution		9,013			4,001			24,254

Total revenues		45,240			44,018			180,460

Cost of revenues from proprietary products		18,202			19,738			83,928
Cost of revenues from distribution		7,922			3,531			20,125

Total cost of revenues		26,124			23,269			104,053

Gross profit		19,116			20,749			76,407

Research and development expenses		2,181			4,246			12,995
Selling and marketing expenses		4,753			4,510			18,455
General and administrative expenses		5,229			4,198			18,724
Other expenses		-			-			-
Operating income (loss)		6,953			7,795			26,233

Financial income		425			534			1,921
Income (expenses) in respect of currency exchange differences and derivatives instruments, net		(261	)		251			(1,171	)
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.		(1,538	)		(1,775	)		(2,652	)
Financial expenses		(188	)		(192	)		(864	)
Income before tax on income		5,391			6,613			23,467
Taxes on income		(1,259	)		(2,649	)		(3,269	)

Net Income (loss)	$	4,132		$	3,964		$	20,198

Other Comprehensive Income (loss):
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met
Gain (loss) on cash flow hedges		90			(114	)		1,069
Net amounts transferred to the statement of profit or loss for cash flow hedges		(273	)		(54	)		(943	)
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan		(11	)		8			21
Total comprehensive income (loss)	$	3,938		$	3,804		$	20,345

Earnings per share attributable to equity holders of the Company:
Basic net earnings per share	$	0.07		$	0.07		$	0.35
Diluted net earnings per share	$	0.07		$	0.07		$	0.35

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-3

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

			Additional		Capital reserve due to translation to			Capital reserve			Capital reserve from share			Capital reserve from
	Share		paid in		presentation			from			based			employee			Accumulated			Total
	capital		capital		currency			hedges			payments			benefits			deficit			equity
	Unaudited
	U.S. Dollars in Thousands
Balance as of January 1, 2026 (audited)	$	15,078	$	268,283	$	(3,490	)	$	177		$	5,711		$	385		$	(17,074	)	$	269,070
Net income		-		-		-			-			-			-			4,132			4,132
Other comprehensive income (loss), net of tax		-		-		-			(183	)		-			(11	)		-			(194	)
Total comprehensive income (loss)		-		-		-			(183	)		-			(11	)		4,132			3,938
Exercise and forfeiture of share-based payment into shares		-		77		-			-			(77	)		-			-			-
Cost of share-based payment		-		-		-			-			800			-			-			800
Dividend declared ($0.25 per share)		-		-		-			-			-			-			(14,421	)		(14,421	)
Balance as of March 31, 2026	$	15,078	$	268,360	$	(3,490	)	$	(6	)	$	6,434		$	374		$	(27,363	)	$	259,387

			Additional		Capital reserve due to translation to			Capital reserve			Capital reserve from share			Capital reserve from
	Share		paid in		presentation			from			based			employee		Accumulated			Total
	capital		capital		currency			hedges			payments			benefits		deficit			equity
	Unaudited
	U.S. Dollars in Thousands
Balance as of January 1, 2025 (audited)	$	15,028	$	266,933	$	(3,490	)	$	51		$	6,316		$	364	$	(25,738	)	$	259,464
Net income		-		-		-			-			-			-		3,964			3,964
Other comprehensive income (loss), net of tax		-		-		-			(168	)		-			8		-			(160	)
Total comprehensive income (loss)		-		-		-			(168	)		-			8		3,964			3,804
Exercise and forfeiture of share-based payment into shares		46		1,227		-			-			(1,227	)		-		-			46
Cost of share-based payment		-		-		-			-			177			-		-			177
Dividend declared ($0.20 per share)		-		-		-			-			-			-		(11,534	)		(11,534	)
Balance as of March 31, 2025	$	15,074	$	268,160	$	(3,490	)	$	(117	)	$	5,266		$	372	$	(33,308	)	$	251,957

F-4

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

	Share		Additional paid in			Capital reserve due to translation to presentation			Capital reserve from		Capital reserve from share based			Capital reserve from employee		Accumulated			Total
	capital		capital			currency			hedges		payments			benefits		deficit			equity
	U.S. Dollars in Thousands
Balance as of January 1, 2025 (audited)	$	15,028	$	266,933		$	(3,490	)	$	51	$	6,316		$	364	$	(25,738	)	$	259,464
Net income		-		-			-			-		-			-		20,198			20,198
Other comprehensive income (loss), net of tax)		-		-			-			126		-			21		-			147
Total comprehensive income (loss)		-		-			-			126		-			21		20,198			20,345
Exercise and forfeiture of share-based payment into shares		50		1,450			-			-		(1,450	)		-		-			50
Cost of share-based payment		-		-			-			-		845			-		-			845
Dividend declared ($0.20 per share)		-		-			-			-		-			-		(11,534	)		(11,534	)
Income tax impact associated with issuance of shares		-		(100	)		-			-		-			-		-			(100	)
Balance as of December 31, 2025	$	15,078	$	268,283		$	(3,490	)	$	177	$	5,711		$	385	$	(17,074	)	$	269,070

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-5

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

	Three months period						Year Ended
	Ended March 31,						December 31,
	2026			2025			2025
	Unaudited			Unaudited
	U.S. Dollars in Thousands
Cash Flows from Operating Activities
Net income	$	4,132		$	3,964		$	20,198

Adjustments to reconcile net income to net cash provided by operating activities:

Adjustments to the profit or loss items:

Depreciation and amortization		3,851			3,611			14,918
Financial expenses, net		1,562			1,182			2,766
Cost of share-based payment		800			175			845
Taxes on income		1,259			2,649			3,269
Gain from sale of property and equipment		-			(8	)		(8	)
Change in employee benefit liabilities, net		31			16			183
		7,503			7,625			21,973
Changes in asset and liability items:

Increase in trade receivables, net		(9,757	)		(6,557	)		(5,407	)
Decrease (increase) in other accounts receivables		1,288			(671	)		(535	)
Decrease (increase) in inventories		(494	)		461			(6,124	)
Decrease in deferred expenses		119			94			475
Decrease in trade payables		(1,446	)		(3,748	)		(6,870	)
Increase (decrease) in other accounts payables		(1,897	)		(2,044	)		950
Increase (decrease) in deferred revenues		67			34			(171	)
		(12,120	)		(12,431	)		(17,682	)
Cash received (paid) during the period for:

Interest paid		(187	)		(176	)		(864	)
Interest received		425			534			1,921
Taxes paid		(44	)		(29	)		(56	)
		194			329			1,001

Net cash provided by (used in) operating activities	$	(291	)	$	(513	)	$	25,490

F-6

KAMADA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

	Three months period						Year Ended
	Ended March, 31						December 31,
	2026			2025			2025
	Unaudited			Unaudited
	U.S. Dollars in Thousands
Cash Flows from Investing Activities
Purchase of property and equipment and intangible assets	$	(973	)	$	(1,468	)	$	(9,846	)
Investment in short term investments, net		(40,225	)		-			-
Proceeds from sale of property and equipment		-			8			8
Net cash used in investing activities		(41,198	)		(1,460	)		(9,838	)

Cash Flows from Financing Activities

Proceeds from exercise of share base payments		-			46			50
Repayment of lease liabilities		(389	)		(14	)		(972	)
Dividends Paid		-			-			(11,534	)
Repayment of other long-term liabilities		(467	)		(325	)		(5,889	)
Net cash used in financing activities		(856	)		(293	)		(18,345	)

Exchange differences on balances of cash and cash equivalent		(202	)		81			(273	)

Decrease in cash and cash equivalents		(42,547	)		(2,185	)		(2,966	)

Cash and cash equivalents at the beginning of the period		75,469			78,435			78,435

Cash and cash equivalents at the end of the period	$	32,922		$	76,250		$	75,469

Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability	$	439		$	352		$	1,221
Purchase of property and equipment and Intangible assets	$	683		$	1,103		$	2,523

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-7

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 1:- General

General description of the Company and its activity

Kamada Ltd (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B® , as well as KAMRAB® and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel and the MENA region through in-licensing partnerships including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

In November 2021, the Company acquired, pursuant to an Asset Purchase Agreement, CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B from Saol Therapeutics Ltd. The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers.

In accordance with an agreement with Takeda Pharmaceuticals Company Limited (“Takeda”), starting from the first quarter of 2022, Takeda pays the Company royalties on sales of GLASSIA manufactured by Takeda in the United States and, commencing in 2024, in Canada, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each year from 2022 to 2040. The Company will also be entitled to royalty income on sales of GLASSIA by Takeda in Australia and New Zealand, to the extent that GLASSIA will be approved, and sales will be generated in these markets by Takeda in the future.

The Company’s ordinary shares are listed for trading on the Tel Aviv Stock Exchange and the NASDAQ Global Select Market.

FIMI Opportunity Funds (“FIMI”), the leading private equity firm in Israel beneficially owns approximately 38% of the Company’s outstanding ordinary shares and is a controlling shareholder of the Company; within the meaning of the Israeli Companies Law, 1999.

The Company’s activity is divided into two operating segments:

Proprietary Products		Manufacturing, sales and distribution of plasma-derived protein therapeutics and normal source plasma.

Distribution		Distribute imported drug products in Israel and MENA region, which are manufactured by third parties.

The Company has four wholly-owned subsidiaries – Kamada Inc., Kamada Plasma LLC (wholly owned by Kamada Inc.), KI Biopharma LLC and Kamada Ireland Limited. In addition, the Company owns 74% of Kamada Assets Ltd. (“Kamada Assets”).

F-8

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 2:- Material Accounting Policies

Basis of preparation of the interim consolidated financial statements:

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”.

Forthcoming requirements

Presentation and Disclosure in Financial Statements – IFRS 18

In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (“IFRS 18”) which replaces IAS 1 Presentation of Financial Statements. IFRS 18 requires an entity to classify all income and expenses within its statement of profit and loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new. These categories are complemented by the requirement to present subtotals for “operating profit or loss,” profit or loss before financing income and taxes” and “profit or loss” IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted.

The Company is currently assessing the impact of the Standard on its financial statements. As of March 31, 2026, the Company does not have impact on its financial statement.

Note 3:- Significant events in the reporting period

On March 11, 2026, the company announced that its Board of Directors has declared a special cash dividend of $0.25 (NIS 0.77) per share on the Company’s common stock (totaling $14,421 thousands). The special cash dividend was paid on April 7, 2026, to shareholders of record at the close of business on March 23, 2026.

F-9

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 4:- Operating Segments

General:

The company has two operating segments, as follows:

Proprietary Products		Manufacturing, sales and distribution of plasma-derived protein therapeutics and normal source plasma.

Distribution		Distribute imported drug products in Israel and MENA region, which are manufactured by third parties.

Reporting on operating segments:

	Three months period ended March 31, 2026
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited

Revenues	$	36,227	$	9,013	$	45,240
Gross profit	$	18,025	$	1,091	$	19,116
Unallocated corporate expenses						(12,163	)
Finance expenses, net						(1,562	)
Income before taxes on income					$	5,391

	Three months period ended March 31, 2025
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Revenues	$	40,017	$	4,001	$	44,018
Gross profit	$	20,279	$	470	$	20,749
Unallocated corporate expenses						(12,954	)
Finance expenses, net						(1,182	)
Income before taxes on income					$	6,613

F-10

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 4:- Operating Segments (cont.)

Reporting on operating segments (cont.):

	Year Ended December 31, 2025
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Audited
Revenues	$	156,206	$	24,254	$	180,460
Gross profit	$	72,278	$	4,129	$	76,407
Unallocated corporate expenses						(50,174	)
Finance expenses, net						(2,766	)
Income before taxes on income					$	23,467

Reporting on operating segments by geographic region:

	Three months period ended March 31, 2026
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A	$	22,106	$	-	$	22,106
Israel		3,155		9,013		12,168
Latin America		4,792		-		4,792
Canada		3,315		-		3,315
Asia		548		-		548
Europe		1,743		-		1,743
Other		568				568
	$	36,227	$	9,013	$	45,240

F-11

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 4:- Operating Segments (cont.)

Reporting on operating segments by geographic region: (cont.)

	Three months period ended March 31, 2025
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A	$	30,157	$	-	$	30,157
Israel		1,353		4,001		5,354
Canada		4,611		-		4,611
Asia		3,036		-		3,036
Latin America		790		-		790
Europe		70		-		70
	$	40,017	$	4,001	$	44,018

	Year ended December 31, 2025
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Audited
Geographical markets
U.S.A	$	99,644	$	-	$	99,644
Israel		5,309		24,254		29,563
Latin America		24,223		-		24,223
Canada		10,805		-		10,805
Europe		9,449		-		9,449
Asia		6,720		-		6,720
Others		56		-		56
	$	156,202	$	24,254	$	180,456

F-12

KAMADA LTD.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 5:- Financial Instruments

Classification of financial instruments by fair value hierarchy

Financial assets (liabilities) measured at fair value

	Level 1		Level 2			Level 3
	U.S Dollars in thousands
March 31, 2026
Derivatives instruments	$	-	$	7		$	-
Contingent consideration	$	-	$	-		$	(23,776	)

March 31, 2025
Derivatives instruments		-	$	(154	)	$	-
Contingent consideration	$	-	$	-		$	(24,216	)

December 31, 2025
Derivatives instruments	$	-	$	197		$	-
Contingent consideration	$	-	$	-		$	(23,237	)

During the three months ended on March 31, 2026, there were no transfers due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument.

Note 6:- Subsequent events

With respect to a dividend payment made on April 7, 2026 please refer to Note 3 above.

F-13